In the News: Interview with an Innovator

Virginia Business Magazine Features ivWatch in May 2019 Issue

ivWatch President and CEO, Gary Warren, shares his perspective on what it takes develop a startup into a category-leading medical device manufacturer and biosensor technology company. In the VirginiaBusiness.com article, “Interview with an Innovator,” Warren describes high expectations and medical device design standards, as well as ivWatch’s relentless pursuit of solving an unmet need in health care. The interview, also in the May 2019 print issue, is available here.

ivWatch Becomes Tech Center Research Park Anchor

Medical device manufacturer welcomed by Newport News innovation hub

NEWPORT NEWS, Va., April 16, 2019 – ivWatch, a medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, announced today the lease signing as the anchor organization of Newport News Tech Center Research Park’s Building One. The company is relocating from its Hampton headquarters and Williamsburg research & development (R&D) facility, combining all departments under one roof.

“The move signifies our ongoing investment in the region and aligns our strong history of medical innovation with this budding business and entrepreneurial community,” said Gary Warren, president and CEO of ivWatch. “The Research Park is the type of space we need to expand our clinical and R&D efforts, execute manufacturing and national and international distribution of our product, all while maintaining essential business functions like operations, sales and marketing.”

As the anchor tenant occupying more than 25,500 sq. ft., the building will include exterior ivWatch signage. The first-floor manufacturing space will be housed within sleek glass walls, and state-of-the-art R&D and office space will be located on the third floor.

The ivWatch move-in is slated to be complete by mid-2019, and a ribbon-cutting for Building One is planned for August 2019.

To learn more about ivWatch, visit www.ivWatch.com. To learn more about Tech Center Research Park, visit innovateattechcenterva.com.

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Emphasizes Surveillance Monitoring Benefits to Nurse Leaders at AONE

SAN DIEGO, March 28, 2019 – ivWatch will showcase their solution that aids in the early detection of a common complication of peripheral intravenous (IV) therapy at the 2019 American Organization of Nurse Executives (AONE) Annual Meeting and Exposition on April 10-13, 2019 in San Diego. As part of ongoing efforts to educate on the prevalence of IV complications and the importance of surveillance monitoring to improve patient safety, the company will host open in-booth presentations for attendees to learn more about the economic impacts of peripheral IV infiltration/extravasation injuries.

The session, “Infiltration Impact on Quality and Cost of Care” facilitated by Susan Brown MSN, MSED, VA-BC, the chief nursing officer at ivWatch, will repeat in the company’s booth (#412) during regular exhibition hall hours on:

  • Thursday, April 11: 10:00 a.m. and 12:30 p.m.
  • Friday, April 12: 10:00 a.m. and 12:30 p.m.

“Complications from peripheral IV’s have recently been addressed as a systemic issue facing health systems by the independent patient-safety organization, ECRI Institute, in their Top 10 Patient Safety Concerns for 2019 report*,” said Brown. “I am thrilled to have the opportunity to speak with nursing leadership from across the country on the new advancements in vascular access, and how to harness technology to improve quality and outcomes in this area.”

Additionally, the ivWatch Model 400 will be featured in-booth. The first-of-its-kind continuous monitoring device offers early detection of infiltrations/extravasations, minimizing the risks of IV therapy.

To learn more about ivWatch and upcoming event participation, visit www.ivWatch.com/events/.

*https://www.ecri.org/landing-top-10-patient-safety-concerns-2019

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

In the News: Infusion Pump Misconceptions

ivWatch on How Infusion Pump Companies Risk Patient Safety

ivWatch Executive Vice President of Sales and Business Development, Scott Hensley, addresses an infusion pump pressure alarm misconception in the area of infiltration detection, and its potential for patient harm in the MedTech Intelligence article, “Product Myths Put Patient Safety at Risk.” He discusses the importance of transparency from the medical device industry to hospitals, so they are best equipped to use technology to impact and provide better clinical outcomes for the patient. Read the full article here.

In the News: Health Care Heroes Award

ivWatch Chief Medical Officer, Dr. Brian Clare, was named a 2019 Health Care Hero for the ‘Innovations in Health Care’ category. Read more on this special report by Inside Business here.

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest